Pivotal bioVenture Partners Investment Advisor LLC
Net buyer this quarter
$308M
13
+$33.5M
95.1%
Holdings
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026 | |||||
 PCVX | $82.9M | 26.92% | 0.98% | +3.9% | Q4 2020 |
 ARQT | $33.2M | 10.78% | 1.01% | -6.7% | Q4 2020 |
 TRVI | $32.5M | 10.56% | 1.22% | +12.2% | Q2 2025 |
 AVLN | $31.8M | 10.34% | 2.18% | New | Q2 2026 |
 EVMN | $25.6M | 8.32% | 5.31% | Not reported | Q4 2025 |
 MPLT | $21.9M | 7.12% | 1.35% | 0.0% | Q4 2025 |
 OCS | $20.9M | 6.79% | Not reported | -10.4% | Q1 2023 |
 BIOA | $16M | 5.20% | 1.43% | Not reported | Q3 2024 |
 IMNM | $15.5M | 5.04% | 0.65% | Not reported | Q3 2025 |
 ZBIO | $12.5M | 4.05% | 0.77% | -17.1% | Q3 2024 |
 AVTX | $8.02M | 2.61% | 0.82% | +46.7% | Q1 2026 |
 RLYB | $4.81M | 1.56% | 5.66% | Not reported | Q3 2021 |
 RXRX | $2.19M | 0.71% | 0.11% | Not reported | Q4 2024 |
| Q1 2026 | |||||
| PCVX | $79.8M | 28.51% | 0.95% | Not reported | Q4 2020 |
| OCS | $44.7M | 15.97% | Not reported | -26.6% | Q1 2023 |
| EVMN | $44.3M | 15.83% | 5.35% | Not reported | Q4 2025 |
| ARQT | $31.9M | 11.42% | 1.08% | -0.8% | Q4 2020 |
| TRVI | $18.5M | 6.63% | 1.21% | +23.6% | Q2 2025 |
| IMNM | $16M | 5.73% | 0.65% | Not reported | Q3 2025 |
| MPLT | $12.4M | 4.44% | 1.35% | Not reported | Q4 2025 |
| ZBIO | $11.6M | 4.14% | 0.95% | Not reported | Q3 2024 |
| BIOA | $11.4M | 4.08% | 1.47% | Not reported | Q3 2024 |
| AVTX | $4.42M | 1.58% | 1.20% | New | Q1 2026 |
| RLYB | $2.7M | 0.96% | 5.68% | 0.0% | Q3 2021 |
| RXRX | $1.83M | 0.65% | 0.11% | Not reported | Q4 2024 |
 BOLT | $172K | 0.06% | 2.22% | -55.0% | Q1 2021 |
| Q4 2025 | |||||
| PCVX | $63.3M | 24.48% | 1.05% | Not reported | Q4 2020 |
| OCS | $45.7M | 17.67% | Not reported | -0.5% | Q1 2023 |
| ARQT | $39.7M | 15.34% | 1.11% | -35.6% | Q4 2020 |
| EVMN | $33M | 12.75% | 6.11% | New | Q4 2025 |
| ZBIO | $21.5M | 8.31% | 1.09% | -24.0% | Q3 2024 |
| TRVI | $15.7M | 6.08% | 0.98% | Not reported | Q2 2025 |
| IMNM | $15.7M | 6.08% | 0.65% | +45.8% | Q3 2025 |
| MPLT | $10.7M | 4.15% | 1.39% | New | Q4 2025 |
| BIOA | $8.64M | 3.34% | 1.75% | Not reported | Q3 2024 |
| RXRX | $2.44M | 0.94% | 0.11% | Not reported | Q4 2024 |
| RLYB | $1.65M | 0.64% | 45.51% | Not reported | Q3 2021 |
| BOLT | $517K | 0.20% | 4.92% | Not reported | Q1 2021 |
| Q3 2025 | |||||
| PCVX | $49.4M | 28.58% | 1.06% | +5.2% | Q4 2020 |
| OCS | $40.4M | 23.38% | Not reported | Not reported | Q1 2023 |
| ARQT | $40M | 23.11% | 1.76% | Not reported | Q4 2020 |
| ZBIO | $17.3M | 10.00% | 1.85% | Not reported | Q3 2024 |
| TRVI | $11.5M | 6.65% | 0.98% | +9.7% | Q2 2025 |
| IMNM | $5.88M | 3.40% | 0.55% | New | Q3 2025 |
| BIOA | $3.84M | 2.22% | 1.82% | Not reported | Q3 2024 |
| RXRX | $2.91M | 1.68% | 0.12% | Not reported | Q4 2024 |
| RLYB | $1.2M | 0.69% | 5.73% | Not reported | Q3 2021 |
| BOLT | $503K | 0.29% | 4.93% | Not reported | Q1 2021 |